Skip to content
Screener

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Eli Lilly logo
Eli LillyLLY
-$3.47B-351%
Pfizer logo
PfizerPFE
-$2.86B+45.4%
Merck & Co. logo
Merck & Co.MRK
-$2.98B+48.2%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$549.89M+812%

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$38.79B+460%
Enterprise value$38.5B+479%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-208969
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock under equity incentive plans12,209891
Exercise of warrants571
Deferred offering costs(252)(18)
Net cash provided by financing activities238,744874
Net increase (decrease) in cash, cash equivalents and restricted cash57,194(209,510)
Cash, cash equivalents and restricted cash - beginning of period388,603546,762
Cash, cash equivalents and restricted cash - end of period$445,797$337,252
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s financing cash flow?
Revolution Medicines, Inc. (RVMD) reported financing cash flow of $238.74M in Q1 2026.
How has Revolution Medicines, Inc.'s financing cash flow changed year-over-year?
Revolution Medicines, Inc.'s financing cash flow increased by 27216.2% year-over-year, from $874K to $238.74M.
What is the long-term trend for Revolution Medicines, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s financing cash flow has grown at a 20.6% compound annual growth rate (CAGR), from $294.18M to $623.12M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Revolution Medicines, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude